Rapid Build of HIV Related Protective Barriers

Not Applicable

• Conditions: Viral Suppression of HIV Infection
• Interventions: Drug: The dosage of 400mg EFV; Behavioral: Personal involved intervention strategies

• Registration Number: NCT03852849
• Lead Sponsor: National Center for AIDS/STD Control and Prevention, China CDC

Brief Summary

The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.

Detailed Description

Sexual transmission became the primary route of HIV transmission in China and heterosexual transmission also contributed greatly to HIV epidemic which was mostly reported in South-west rural areas. In past years, Yunnan has experienced powerful campaign of scaling-up the HIV identification as well as antrertroviral therapy.

This study will investigate how to reach the last two of HIV'90-90-90 targets': to provide antiretroviral therapy (ART) for 90% of who diagnosed HIV infection and to achieve viral suppression for 90% of those treated.

The study population consists of participants who received an newly diagnosed HIV infection within the study period. All rerolled participants will be randomized into different study group. In intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg EFV in their antiviral therapy.

Main assessment measures are viral suppression rate of HIV-infected patients and treatment coverage .

Study Timeline

• Status Verified: 2019-02
• Study First Submitted: 2019-02-22
• Study First Submitted QC: 2019-02-22
• Last Update Submitted: 2019-02-22
• Study First Posted: 2019-02-25
• Last Update Posted: 2019-02-25
• Study Start: 2019-03-01
• Primary Completion: 2020-12-31
• Study Completion: 2021-03-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• HIV-positive participants who received an newly diagnosed HIV infection within the study period
• Having a current residential address inside of pilot site limits
• Eighteen years old or above
• HIV transmission is heterosexual contact

Exclusion Criteria

• IDU
• Having severe mental disorder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
medicine intervention group	The dosage of 400mg EFV	The dosage of 400 mg EFV will be used in the antiviral therapy.
consolidated intervention group	Personal involved intervention strategies	Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.
consolidated intervention group	The dosage of 400mg EFV	Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.

Primary Outcome Measures

Name	Time	Method
Viral suppression of HIV-infected patients	12 months

Secondary Outcome Measures

Name	Time	Method
Treatment coverage	12 months

Trial Locations

Locations (2)

Lincang Center for Disease Control and Prevention; 🇨🇳 Lincang, Yunnan, China

Wenshan Center for Disease Control and Prevention; 🇨🇳 Wenshan, Yunnan, China